What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Antibiotics
- Surgery
His main research concerns Antibacterial agent, Microbiology, Pharmacokinetics, Antibiotics and Pharmacodynamics.
His research in Antibacterial agent intersects with topics in Anesthesia, Surgery, Meropenem, Tobramycin and Aminoglycoside.
His Microbiology research is multidisciplinary, relying on both Pseudomonas aeruginosa, Klebsiella pneumoniae, In vivo and Staphylococcus aureus.
Pharmacokinetics is a subfield of Pharmacology that David P. Nicolau tackles.
His study in Antibiotics is interdisciplinary in nature, drawing from both Area under the curve and Intensive care medicine.
His Pharmacodynamics study combines topics from a wide range of disciplines, such as Telithromycin and Tazobactam.
His most cited work include:
- Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. (498 citations)
- Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. (216 citations)
- Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection (200 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Microbiology, Antibiotics, Pharmacokinetics, Pharmacodynamics and Antibacterial agent.
David P. Nicolau interconnects Pseudomonas aeruginosa, Klebsiella pneumoniae, In vivo and Staphylococcus aureus in the investigation of issues within Microbiology.
In his research, Antibiotic resistance is intimately related to Intensive care medicine, which falls under the overarching field of Antibiotics.
The various areas that he examines in his Pharmacokinetics study include Gastroenterology and Anesthesia.
His Pharmacodynamics research is multidisciplinary, incorporating elements of Regimen, Minimum inhibitory concentration, Cephalosporin and Dosing.
His Antibacterial agent research is multidisciplinary, incorporating perspectives in Aminoglycoside and Streptococcus pneumoniae.
He most often published in these fields:
- Microbiology (40.50%)
- Antibiotics (26.87%)
- Pharmacokinetics (23.38%)
What were the highlights of his more recent work (between 2018-2021)?
- Microbiology (40.50%)
- Pseudomonas aeruginosa (16.50%)
- Meropenem (17.25%)
In recent papers he was focusing on the following fields of study:
David P. Nicolau mainly focuses on Microbiology, Pseudomonas aeruginosa, Meropenem, Pharmacokinetics and Pharmacodynamics.
The Microbiology study combines topics in areas such as In vitro and In vivo.
David P. Nicolau has included themes like Amikacin, Enterobacterales and Pneumonia in his Pseudomonas aeruginosa study.
The Pharmacokinetics portion of his research involves studies in Pharmacology and Internal medicine.
David P. Nicolau works mostly in the field of Pharmacology, limiting it down to topics relating to Antimicrobial and, in certain cases, Antibiotic resistance, as a part of the same area of interest.
In his study, Vancomycin and Intensive care medicine is strongly linked to Antibiotics, which falls under the umbrella field of Pharmacodynamics.
Between 2018 and 2021, his most popular works were:
- Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint (23 citations)
- Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial (20 citations)
- Evaluation of the EDTA-Modified Carbapenem Inactivation Method for Detecting Metallo-β-Lactamase-Producing Pseudomonas aeruginosa (19 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Antibiotics
- Bacteria
His scientific interests lie mostly in Microbiology, Pseudomonas aeruginosa, Meropenem, Pharmacodynamics and Antibiotics.
David P. Nicolau combines subjects such as Klebsiella pneumoniae, In vitro and In vivo with his study of Microbiology.
His Meropenem study combines topics in areas such as Ceftazidime, Aztreonam, Potency and Fosfomycin.
His Pharmacodynamics study results in a more complete grasp of Pharmacokinetics.
His Pharmacokinetics study incorporates themes from Gastroenterology and Renal function.
His studies deal with areas such as Vancomycin, Dosing and Intensive care medicine as well as Antibiotics.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
